. . "5"^^ . "vorapaxar; myocardial infarction; secondary prevention"@en . "Vorapaxar v klinick\u00FDch studi\u00EDch" . "CZ - \u010Cesk\u00E1 republika" . . . "Kardiologick\u00E1 revue" . . "I" . . . "14" . "\u0160pinarov\u00E1, Lenka" . "RIV/00216224:14110/12:00062784" . "RIV/00216224:14110/12:00062784!RIV13-MSM-14110___" . "\u0160pinar, Jind\u0159ich" . . . "Vorapaxar v klinick\u00FDch studi\u00EDch"@cs . "1212-4540" . "Vorapaxar v klinick\u00FDch studi\u00EDch"@cs . . "Dosavadn\u00ED protidesti\u010Dkov\u00E1 strategie u akutn\u00EDch i chronick\u00FDch stav\u016F m\u00E1 z\u00E1va\u017Enou slabinu \u2013 tou je selh\u00E1n\u00ED l\u00E9\u010Dby \u010Di sn\u00ED\u017Een\u00ED l\u00E9\u010Debn\u00E9 odpov\u011Bdi u v\u00FDznamn\u00E9ho procenta l\u00E9\u010Den\u00FDch. V\u00FDsledkem je p\u0159etrv\u00E1v\u00E1n\u00ED hyperaktivace trombocyt\u016F a riziko rozvoje trombotick\u00E9 komplikace. Sch\u016Fdnou a logickou cestou je proto p\u0159echod na l\u00E9\u010Dbu \u00FA\u010Dinn\u011Bj\u0161\u00EDmi p\u0159\u00EDpravky. Takov\u00FDmi p\u0159\u00EDpravky jsou dnes ji\u017E dostupn\u00FD ireverzibiln\u00ED inhibitor receptoru ADP, tj. prasugrel, \u010Di inhibitor reverzibiln\u00ED, tj. ticagrelor. V tomto \u010Dl\u00E1nku uv\u00E1d\u00EDme v\u00FDsledky klinick\u00E9ho zkou\u0161en\u00ED s inhibitorem desti\u010Dkov\u00FDch receptor\u016F PAR 1 \u2013 vorapaxarem (SCH530348). Studie TRACER je mezin\u00E1rodn\u00ED klinick\u00E1 studie u 12 944 nemocn\u00FDch s akutn\u00EDm koron\u00E1rn\u00EDm syndromem s ST elevacemi. Prim\u00E1rn\u00ED c\u00EDl byl slo\u017Een\u00FD z \u00FAmrt\u00ED na kardiovaskul\u00E1rn\u00ED p\u0159\u00ED\u010Diny, infarktu myokardu, c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody, hospitalizace pro ischemii nebo urgentn\u00ED revaskularizace. Studie byla p\u0159ed\u010Dasn\u011B ukon\u010Dena po vyhodnocen\u00ED bezpe\u010Dnosti pod\u00E1van\u00E9 medikace."@cs . "Current anti-platelet strategies for acute and chronic cases have one serious weakness \u2013 the failure of therapy or reduced response to therapy in a significant percentage of patients. The result of this is the ongoing hyperactivity of thrombocytes and the risk of development of thrombotic complications. One practical and logical solution would therefore be the introduction of treatment using more effective substances, such as the now-available prasugrel, an irreversible ADP inhibitor, and ticagrelor, a reversible inhibitor. This article presents the results of a clinical test using vorapaxar (SCH530348), a PAR-1 inhibitor for platelet receptors. The TRACER study is an international clinical study of 12,944 patients with acute coronary syndrome with ST elevations. The study primarily focused on mortality due to cardiovascular causes, myocardial infarctions, strokes, hospitalisation for ischemia or urgent revascularisation."@en . "2" . "V\u00EDtovec, Ji\u0159\u00ED" . "[FA2010A2A1BA]" . "3"^^ . "Dosavadn\u00ED protidesti\u010Dkov\u00E1 strategie u akutn\u00EDch i chronick\u00FDch stav\u016F m\u00E1 z\u00E1va\u017Enou slabinu \u2013 tou je selh\u00E1n\u00ED l\u00E9\u010Dby \u010Di sn\u00ED\u017Een\u00ED l\u00E9\u010Debn\u00E9 odpov\u011Bdi u v\u00FDznamn\u00E9ho procenta l\u00E9\u010Den\u00FDch. V\u00FDsledkem je p\u0159etrv\u00E1v\u00E1n\u00ED hyperaktivace trombocyt\u016F a riziko rozvoje trombotick\u00E9 komplikace. Sch\u016Fdnou a logickou cestou je proto p\u0159echod na l\u00E9\u010Dbu \u00FA\u010Dinn\u011Bj\u0161\u00EDmi p\u0159\u00EDpravky. Takov\u00FDmi p\u0159\u00EDpravky jsou dnes ji\u017E dostupn\u00FD ireverzibiln\u00ED inhibitor receptoru ADP, tj. prasugrel, \u010Di inhibitor reverzibiln\u00ED, tj. ticagrelor. V tomto \u010Dl\u00E1nku uv\u00E1d\u00EDme v\u00FDsledky klinick\u00E9ho zkou\u0161en\u00ED s inhibitorem desti\u010Dkov\u00FDch receptor\u016F PAR 1 \u2013 vorapaxarem (SCH530348). Studie TRACER je mezin\u00E1rodn\u00ED klinick\u00E1 studie u 12 944 nemocn\u00FDch s akutn\u00EDm koron\u00E1rn\u00EDm syndromem s ST elevacemi. Prim\u00E1rn\u00ED c\u00EDl byl slo\u017Een\u00FD z \u00FAmrt\u00ED na kardiovaskul\u00E1rn\u00ED p\u0159\u00ED\u010Diny, infarktu myokardu, c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhody, hospitalizace pro ischemii nebo urgentn\u00ED revaskularizace. Studie byla p\u0159ed\u010Dasn\u011B ukon\u010Dena po vyhodnocen\u00ED bezpe\u010Dnosti pod\u00E1van\u00E9 medikace." . "Vorapaxar v klinick\u00FDch studi\u00EDch" . "3"^^ . . . "Vorapaxar in clinical studies"@en . . . . . "Vorapaxar in clinical studies"@en . "178579" . "14110" . .